Hospital
Cheshire Medical Center
Cheshire Medical Center was paid $8.71M by Medicaid between Jan 2018 and Nov 2024, across 270 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoCHESHIRE MEDICAL CENTER
KEENE, NH 03431
KEENE, NH 03431
33aNPI1952415812assigned 08/18/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$8.71M
24GClaims478,297
24DCodes billed270
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,732 | $1.13M | |
| 2019 | 99,619 | $1.76M | |
| 2020 | 100,344 | $2.26M | |
| 2021 | 112,732 | $2.40M | |
| 2022 | 45,854 | $928K | |
| 2023 | 20,368 | $124K | |
| 2024incomplete | 15,648 | $100K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 10,304 | 7,790 | $934K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.9% | 2,557 | 2,032 | $776K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 6,746 | 5,197 | $761K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 6.7% | 11,607 | 9,676 | $581K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.6% | 5,391 | 4,618 | $399K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.5% | 43,432 | 24,097 | $396K |
| G0378 | Hospital observation service, per hour | 2.6% | 2,125 | 810 | $230K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 13,834 | 5,183 | $229K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 2,443 | 1,859 | $197K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.0% | 305 | 241 | $176K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 9,691 | 7,022 | $166K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 4,832 | 3,183 | $159K |
258 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 718 | $152K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 4,836 | $141K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.6% | 815 | $138K |
| 80053 | Comprehensive metabolic panel | 1.4% | 22,367 | $126K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 695 | $115K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 30,549 | $105K |
| 97161 | 1.2% | 2,052 | $101K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 5,697 | $98K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 4,334 | $92K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 11,256 | $89K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 2,513 | $88K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,750 | $84K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 279 | $70K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 542 | $68K |
| 73630 | <1% | 1,533 | $63K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,055 | $58K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,060 | $58K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,780 | $52K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,916 | $51K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,393 | $50K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 608 | $49K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,052 | $48K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,753 | $46K |
| 96376 | <1% | 1,331 | $46K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,614 | $44K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,116 | $43K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,669 | $43K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,698 | $42K |
| 73610 | <1% | 946 | $42K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,320 | $41K |
| 80061 | Lipid panel | <1% | 5,066 | $40K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 372 | $39K |
| 73562 | <1% | 791 | $38K | |
| 73030 | <1% | 967 | $38K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,330 | $38K |
| 87806 | <1% | 2,408 | $35K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,197 | $34K |
| 87800 | <1% | 1,846 | $33K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 146 | $31K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 150 | $30K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,946 | $29K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,086 | $29K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,197 | $29K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,322 | $28K |
| 73130 | <1% | 641 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 325 | $27K |
| 84702 | <1% | 2,645 | $27K | |
| 72100 | <1% | 616 | $26K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 229 | $24K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 608 | $23K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,244 | $21K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 557 | $21K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,698 | $21K |
| 85027 | <1% | 4,787 | $20K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 216 | $20K |
| 86803 | <1% | 1,951 | $20K | |
| 84484 | <1% | 4,524 | $19K | |
| 86850 | <1% | 1,876 | $18K | |
| 80306 | <1% | 2,432 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,679 | $16K |
| 74018 | <1% | 409 | $16K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 107 | $16K |
| 87522 | Neg quan hep c or qual rna | <1% | 505 | $15K |
| 20610 | <1% | 490 | $15K | |
| 83655 | <1% | 1,467 | $15K | |
| 83690 | <1% | 4,434 | $15K | |
| 87150 | <1% | 377 | $14K | |
| 82728 | <1% | 1,649 | $14K | |
| 83880 | <1% | 1,116 | $14K | |
| 73110 | <1% | 363 | $13K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,191 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 943 | $12K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 393 | $11K |
| 84439 | <1% | 2,058 | $11K | |
| 11721 | <1% | 1,654 | $11K | |
| 86780 | <1% | 1,123 | $11K | |
| 87340 | <1% | 1,517 | $10K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 541 | $10K |
| 87186 | <1% | 2,133 | $10K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 404 | $10K |
| 80076 | <1% | 2,088 | $10K | |
| 81025 | <1% | 2,724 | $10K | |
| 81001 | <1% | 6,478 | $10K | |
| 86140 | <1% | 3,189 | $9K | |
| 83605 | <1% | 1,920 | $9K | |
| 82607 | <1% | 1,499 | $9K | |
| 82803 | <1% | 882 | $9K | |
| 85610 | <1% | 5,074 | $9K | |
| 94726 | <1% | 127 | $9K | |
| 87040 | <1% | 939 | $8K | |
| 83550 | <1% | 1,522 | $8K | |
| 73502 | <1% | 251 | $8K | |
| 82784 | <1% | 930 | $7K | |
| 97162 | <1% | 177 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 367 | $7K |
| 80050 | General health panel | <1% | 886 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,823 | $7K |
| 83735 | <1% | 2,687 | $7K | |
| 82962 | <1% | 4,960 | $6K | |
| 87581 | <1% | 371 | $6K | |
| 87486 | <1% | 371 | $6K | |
| 83540 | <1% | 1,555 | $6K | |
| 85379 | <1% | 1,226 | $6K | |
| 93017 | <1% | 108 | $6K | |
| 83516 | <1% | 625 | $5K | |
| 87070 | <1% | 913 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,587 | $5K |
| 86787 | <1% | 512 | $5K | |
| 86762 | <1% | 451 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 21 | $5K |
| 85652 | <1% | 2,902 | $4K | |
| 93971 | <1% | 117 | $4K | |
| 84153 | <1% | 493 | $4K | |
| 86618 | <1% | 436 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $4K |
| 71250 | <1% | 31 | $4K | |
| 86900 | <1% | 1,880 | $4K | |
| 84403 | <1% | 192 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 15 | $4K |
| 86706 | <1% | 568 | $4K | |
| 72040 | <1% | 72 | $4K | |
| 87507 | <1% | 26 | $4K | |
| 82043 | <1% | 1,350 | $4K | |
| 81003 | <1% | 4,305 | $4K | |
| 94729 | <1% | 151 | $4K | |
| 82570 | <1% | 1,138 | $4K | |
| 87081 | <1% | 888 | $3K | |
| 76770 | <1% | 34 | $3K | |
| 86901 | <1% | 1,880 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,208 | $3K |
| 87147 | <1% | 448 | $3K | |
| 85730 | <1% | 1,124 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,782 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 159 | $3K |
| 84460 | <1% | 881 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,759 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,097 | $3K |
| 82565 | <1% | 910 | $3K | |
| 94060 | <1% | 32 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 79 | $2K |
| 87205 | <1% | 836 | $2K | |
| 59025 | Fetal non-stress test | <1% | 62 | $2K |
| 83970 | <1% | 87 | $2K | |
| 73140 | <1% | 70 | $2K | |
| 84450 | <1% | 568 | $2K | |
| 73590 | <1% | 33 | $2K | |
| 86704 | <1% | 241 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,595 | $2K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 99 | $2K |
| 84146 | <1% | 110 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 866 | $2K |
| 86038 | <1% | 198 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 526 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,345 | $1K |
| 76536 | <1% | 15 | $1K | |
| 84100 | <1% | 513 | $1K | |
| 80164 | <1% | 188 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 87 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 557 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,670 | $1K |
| 86480 | <1% | 28 | $1K | |
| 82746 | <1% | 125 | $1K | |
| 86708 | <1% | 133 | $1K | |
| 73100 | <1% | 35 | $1K | |
| 97113 | <1% | 38 | $1K | |
| 82950 | <1% | 270 | $1K | |
| 76641 | <1% | 14 | $982.84 | |
| 84145 | <1% | 112 | $957.96 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 46 | $950.29 |
| 87430 | <1% | 108 | $923.94 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,183 | $915.13 |
| 90686 | <1% | 1,060 | $886.19 | |
| 84550 | <1% | 349 | $885.73 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 40 | $885.12 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 540 | $858.84 |
| 94664 | <1% | 60 | $843.08 | |
| 82150 | <1% | 212 | $811.95 | |
| 82977 | <1% | 194 | $794.75 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 27 | $780.86 |
| 86039 | <1% | 95 | $761.53 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 269 | $732.54 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,588 | $710.51 |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 74 | $652.84 |
| 11720 | <1% | 89 | $646.32 | |
| 86431 | <1% | 172 | $630.46 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,067 | $606.28 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 34 | $554.33 |
| 84402 | <1% | 29 | $551.79 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 723 | $502.48 |
| 97116 | <1% | 28 | $491.91 | |
| 90677 | <1% | 64 | $469.40 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 14 | $425.62 |
| 76642 | <1% | 15 | $418.00 | |
| Q3014 | Telehealth originating site facility fee | <1% | 150 | $357.97 |
| 83001 | <1% | 32 | $345.71 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 136 | $337.50 |
| 84156 | <1% | 137 | $335.02 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 91 | $319.81 |
| 90715 | <1% | 19 | $315.19 | |
| 83883 | <1% | 59 | $299.15 | |
| 82040 | <1% | 103 | $269.12 | |
| 80320 | <1% | 38 | $261.25 | |
| 81002 | <1% | 552 | $253.75 | |
| 82247 | <1% | 95 | $247.65 | |
| 85018 | <1% | 159 | $242.81 | |
| 85014 | <1% | 159 | $242.81 | |
| 86200 | <1% | 27 | $241.11 | |
| 82550 | <1% | 79 | $239.14 | |
| 90662 | <1% | 172 | $232.64 | |
| 96127 | <1% | 81 | $190.87 | |
| 80178 | <1% | 54 | $185.08 | |
| 83010 | <1% | 28 | $184.18 | |
| 84132 | <1% | 69 | $171.98 | |
| 90653 | <1% | 157 | $168.10 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 20 | $163.08 |
| 84480 | <1% | 12 | $158.12 | |
| 84075 | <1% | 53 | $154.18 | |
| 84520 | <1% | 55 | $144.09 | |
| 82172 | <1% | 13 | $143.76 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 151 | $142.90 |
| 80177 | <1% | 13 | $139.26 | |
| 90632 | <1% | 50 | $130.96 | |
| 82947 | <1% | 53 | $127.89 | |
| 99152 | <1% | 16 | $126.36 | |
| 82310 | <1% | 44 | $120.52 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 60 | $118.32 |
| 86308 | <1% | 28 | $111.05 | |
| 84155 | <1% | 53 | $110.37 | |
| 80175 | <1% | 15 | $104.76 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 422 | $99.96 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 134 | $95.18 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 144 | $91.21 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 26 | $87.75 |
| 36416 | <1% | 26 | $66.00 | |
| 84295 | <1% | 27 | $65.78 | |
| 82435 | <1% | 27 | $64.99 | |
| 94010 | <1% | 17 | $60.07 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 35 | $55.85 |
| 92015 | Determination of refractive state | <1% | 702 | $46.45 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 98 | $40.57 |
| G0009 | Administration of pneumococcal vaccine | <1% | 151 | $38.96 |
| 82374 | <1% | 13 | $32.99 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 36 | $26.87 |
| 91322 | <1% | 29 | $24.97 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 39 | $9.19 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 92 | $8.02 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 18 | $5.27 |
| 80329 | 0% | 33 | $0.00 | |
| 90694 | 0% | 46 | $0.00 | |
| 90656 | 0% | 57 | $0.00 | |
| 90480 | 0% | 29 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 743 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 100 | $0.00 |
| 0124A | 0% | 17 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 185 | $0.00 |
| 80364 | 0% | 12 | $0.00 | |
| 91312 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARUSO, DON (CEO)
Parent organizationCHESHIRE MEDICAL CENTER
| Provider | Location | Paid |
|---|---|---|
| Cheshire Health Services INC | Keene, NH | $382K |
| Cheshire Medical Center | Keene, NH | $20K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.